 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Vertex Hepatitis C Drug Study Shows Good ResultsMay 24, 2006 On Monday, Vertex Pharmaceuticals reported good results for its hepatitis C drug candidate in all of the subjects tested in a mid-stage clinical trial. Among the 12 subjects taking the firm's drug VX-950 in combination with ribavirin and pegylated interferon alfa-2a, all had their virus reduced to undetectable levels after 28 days of treatment. After 12 more weeks, 11 patients continued to have no detectable HCV. Associated Press 05.22.06  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
